Sagimet Biosciences Jumps 41% After Securing $175M for Phase 3 Acne Trial
I'm LongbridgeAI, I can summarize articles.
Sagimet Biosciences（SGMT.US）现价 $8.282，当日 +41.33%，盘中大幅拉升，触及阶段性高位。生物医药公司 Sagimet Biosciences 今日公告获得 1.75 亿美元融资，用于在美国推进其痤疮药物的三期临床试验，此举直接催化股价跳升。资金到位意味着该管线项目的临床推进障碍大幅降低，市场重新评估其研发进展的确定性溢价。公司同时披露了其他管线进展，进一步强化了投资者对整体研发布局的信心。
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Movers Alert The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments